Results 11 to 20 of about 10,389 (214)

Impaired β-glucocerebrosidase activity and processing in frontotemporal dementia due to progranulin mutations [PDF]

open access: yesActa Neuropathologica Communications, 2019
Loss-of-function mutations in progranulin (GRN) are a major autosomal dominant cause of frontotemporal dementia. Most pathogenic GRN mutations result in progranulin haploinsufficiency, which is thought to cause frontotemporal dementia in GRN mutation ...
Andrew E. Arrant   +12 more
doaj   +2 more sources

Parkinsonisms and Glucocerebrosidase Deficiency: A Comprehensive Review for Molecular and Cellular Mechanism of Glucocerebrosidase Deficiency [PDF]

open access: yesBrain Sciences, 2019
In the last years, lysosomal storage diseases appear as a bridge of knowledge between rare genetic inborn metabolic disorders and neurodegenerative diseases such as Parkinson’s disease (PD) or frontotemporal dementia. Epidemiological studies helped
Emilia M. Gatto   +4 more
doaj   +3 more sources

Integrating Gaucher disease (GD) into mainstream hematological curriculum training. [PDF]

open access: yesHemasphere
HemaSphere, Volume 10, Issue 10, October 2026.
Bradley C   +3 more
europepmc   +2 more sources

A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease [PDF]

open access: yesDisease Models & Mechanisms, 2016
Glucocerebrosidase is a lysosomal hydrolase involved in the breakdown of glucosylceramide. Gaucher disease, a recessive lysosomal storage disorder, is caused by mutations in the gene GBA1.
Wendy Westbroek   +22 more
doaj   +2 more sources

Glucocerebrosidase mutations and Parkinson disease

open access: yesJournal of Neural Transmission, 2022
AbstractThe discovery of glucocerebrosidase (GBA1) mutations as the greatest numerical genetic risk factor for the development of Parkinson disease (PD) resulted in a paradigm shift within the research landscape. Efforts to elucidate the mechanisms behind GBA1-associated PD have highlighted shared pathways in idiopathic PD including the loss and gain ...
Vieira, Sophia R. L.   +1 more
openaire   +2 more sources

Reexamination of the cysteine residues in glucocerebrosidase [PDF]

open access: yesFEBS Letters, 2006
Glucocerebrosidase, the deficient enzyme in Gaucher disease, catalyzes the cleavage of the β‐glycosidic linkage of glucosylceramide. A previous study on the enzyme identified three disulfide bridges and a single sulfhydryl [Lee, Y., Kinoshita, H., Radke, G., Weiler, S., Barranger, J.A. and Tomich, J.M.
Moharram, Ramy   +5 more
openaire   +2 more sources

Glucocerebrosidase: Functions in and Beyond the Lysosome [PDF]

open access: yesJournal of Clinical Medicine, 2020
Glucocerebrosidase (GCase) is a retaining β-glucosidase with acid pH optimum metabolizing the glycosphingolipid glucosylceramide (GlcCer) to ceramide and glucose. Inherited deficiency of GCase causes the lysosomal storage disorder named Gaucher disease (GD). In GCase-deficient GD patients the accumulation of GlcCer in lysosomes of tissue macrophages is
Daphne E.C. Boer   +3 more
openaire   +2 more sources

Mitochondria and quality control defects in a mouse model of Gaucher Disease-links to Parkinson's Disease [PDF]

open access: yes, 2013
Mutations in the glucocerebrosidase (gba) gene cause Gaucher disease (GD), the most common lysosomal storage disorder, and increase susceptibility to Parkinson's disease (PD).
Gegg, ME   +9 more
core   +1 more source

Parkinsonism Associated with Glucocerebrosidase Mutation [PDF]

open access: yesJournal of Clinical Neurology, 2011
Gaucher's disease is an autosomal recessive, lysosomal storage disease caused by mutations of the β-glucocerebrosidase gene (GBA). There is increasing evidence that GBA mutations are a genetic risk factor for the development of Parkinson's disease (PD).
Sunwoo, Mun-Kyung   +3 more
openaire   +3 more sources

Isofagomine Induced Stabilization of Glucocerebrosidase [PDF]

open access: yesChemBioChem, 2008
AbstractStructurally destabilizing mutations in acid β‐glucosidase (GCase) can result in Gaucher disease (GD). The iminosugar isofagomine (IFG), a competitive inhibitor and a potential pharmacological chaperone of GCase, is currently undergoing clinical evaluation for the treatment of GD.
Gregory J, Kornhaber   +6 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy